Zydus Lifesciences to acquire drug brand Nulibry from US co BridgeBio Pharma

Publicly listed, Ahmedabad-based Zydus Lifesciences (formerly Cadila Healthcare) is to acquire the Nulibry (Fosdenopterin) injection brand from Palo Alto, CA (USA)-based BridgeBio Pharma. The product is approved by the US Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, which is an ultra-rare, life-threatening paediatric genetic disorder. Zydus's US unit Sentynl will be responsible for the ongoing development and commercialisation of Nulibry in the US and developing, manufacturing and commercialising it globally. Sentynl will provide cash payments upon the achievement of certain regulatory milestones.